Core Viewpoint - The company expects revenue for the year ending December 31, 2025, to be between approximately 555 million to 585 million, representing a year-on-year increase of about 25.5% to 32.3 [1] - Adjusted net profit (non-IFRS measure) is projected to be between approximately 200 million to 230 million, reflecting a year-on-year increase of about 16.3% to 33.7% [1] Revenue Growth Factors - The revenue growth is primarily attributed to the successful implementation of the molecular strategy [1] - The advantages of the company's integrated contract research, development, and manufacturing organization (CRDMO) platform contribute to this growth [1] - The company has demonstrated industry-leading project delivery timeliness and excellent project execution track record [1] - There is a strong and continuous demand from key clients for the company's services [1]